Evogene Ltd.

Welcome to EpoGen's first quarter 2026 results conference call. All participants are at present in listen-only mode. Following management's formal presentation, we will open the question and answer session. You may send questions via chat. Please type your name and company before your question. As a reminder, this conference is being recorded May 20, 2026. Before we begin, I would like to caution that certain statements made during this earning conference call by Avergent's management will constitute forward-looking statements that relate to future events. This presentation contains forward-looking statements relating to future events, and Avergent LTD, the company, may from time to time make other statements regarding our outlook or expectations for future financial or operating results and or other matters regarding or affecting us that are considered forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995, the PSLRA, and other security laws as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as believe, expect, anticipate, should, planned, estimated, intent, and potential, or was of similar meaning. We are using forward-looking statements in this presentation when we discussed our value drivers, commercialization effort and timing, product development and launches, estimated market size and milestones, pipeline, as well as our capabilities and technology. Such statements are based on current expectation, estimates, projections, and assumptions. Described opinions about future events involve certain risks and uncertainties, which are difficult to predict and are not guarantees of future performance. We do so caution that certain important factors may affect the company's actual results and could cause such results to differ materially from any forward-looking statement that may be made in this presentation. Therefore, actual future events, performance or achievements and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, the aftermath of the recent war between Israel and each of the terrorist groups, Hamas and Hezbollah, Iran and other regional terrorist groups supported by Iran, and any destabilizations in Israel, neighboring territories, or the Middle East region, and those described in greater detail in Evergen's annual report on Form 20F, and in other information Evergen files and furnished with the Israel Security Authorities and the U.S. Securities and Exchange Commission, including those factors under the heading Risk Factors. Acceptance required by applicable security laws. We disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revision to any statement that may be made to reflect future events or developments or changes in expectations, estimates, projections, and assumptions. The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell or any solicitation of any invitation or offer to purchase or subscribe for any securities of Evergen or the company, nor shall the information or any part of it or the fact of its distribution from the basis of or be relied on in connection with any action, contract, commitment or relating thereto or the securities of Evergen or the company. The trademarks include herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our product or services. With us on the line will be Ofer Habib, President and CEO of Evergen, and Polina Rabzin, VP Finance of Evergen. Now I would like to turn the call over to Ofer Habib. Mr. Habib, please go ahead.

Thank you for joining Evogen's first quarter 2026 analyst call. In today's call, I will focus on the significant progress Evogen has made over the past quarter and outline the company's key objectives for this year. Joining me for this part of the presentation are Dr. Gaby Tarsik, the company's chief development officer, and Dr. Dan Gelban, CEO of our subsidiary AgPlanus, which focuses on ag-chemical development. Following our remarks, our VP of Finance, Polina Ravzin, will present the financial results. Then, we will open the call for questions. As stated in our previous call, Apogee's mission is clear and focused. to design novel, highly potent small molecules optimized across multiple parameters for drug development and chemicals by leveraging campus AI, our computational generative AI engine. This mission is guided by a strong objective to direct Evogen's resources toward areas where we believe we can create the greatest substantial value. To execute this mission, we made two key strategic decisions. The first one was to focus all of our technology efforts on our proprietary computational engine, Campus AI. In this context, I would like to emphasize that we strongly believe that technological collaborations are essential for advancing our core platform. This belief was clearly demonstrated in the partnership we announced with Google in 2025. In this collaboration, we successfully developed a breakthrough generative engine capable of designing entirely new molecules structure Molecules that are not only highly novel, but also easier to synthesize and better align with multiple product development requirements. The second strategic decision was to streamline our business activity to concentrate on two highly impact markets where campus AI provides a strong competitive advantage, pharma focused on small molecule drug discovery, and agriculture focused on next-generation agrochemicals. To maximize the value of our technology, we adopt a clear and consistent business model across both domains, which is built on two complementary channels. The first channel is establishing strategic collaboration with industry partners For early stage product development, those collaborations help reduce both our scientific and financial risk while accelerating innovation. The second channel is the advancement of our own internally funded products pipeline. In this channel, our goal is to mature those programs further before entering partnerships. allowing us to secure stronger commercial terms with leading industry players. These slides highlight the collaboration and internal programs Evogen was advancing at the end of 2025. In agriculture, we established two strategic collaborations for herbicide development. One with Bayer and another with Corteva. At the same time, we continue advancing our internal funded program focused on novel septoria fungicide. It is important to note that Evogen Act chemical activities began in 2018 and are carried out through our subsidiary, Act Planus. In parallel, our pharmaceutical activity focused on small molecules drug discovery were launched only at the beginning of 2025 as a division of Avogen. At the end of 2025, our first and only announced collaboration in this field was with Tel Aviv University targeting therapies for metabolic diseases linked to a protein aggregation in blood vessels. Now, I would like to present the company's achievements over the last quarter and to date across those three areas, our core technology platform, our pharma activities, and our artchemical activities. We will begin by reviewing the achievements in the area of our core technology platform, Campus AI. In February this year, we announced our second collaboration with Google aimed at integrating agents into Campus. The collaboration is expected to enable capabilities that currently do not exist in the global small molecule discovery process. Our second collaboration with Google focused on developing advanced AI agents to solve complex scientific challenges. Success in this project will enable Evogen to automatically extract valuable insights from scientific publications and create proprietary datasets. These datasets will help us build highly-accurated computational models for characterizing specific scientific parameters. We will then use those models to support the development of new molecules designed in accordance with the requirements of our target product profiles. Overall, these new capabilities are expected to significantly strengthen Evogen's technological leadership and competitive advantage. We will now proceed to reviewing the achievements and activities in the company's pharma division where the most significant growth occurred this year. In the first quarter of the year, the company announced three new collaborations agreements, two with biotech companies and one with an academic institution. In the following slides, Dr. Gaby Kacik, Evogen's CTO, will elaborate on each collaboration. Gaby?

Thank you, Alfred. I am excited to share with you the progress in the pharma division that has taken place since the beginning of the year. In February, we announced a new collaboration with Systasy Bioscience and Ludwig Maximilian University Hospital in Germany. This collaboration focuses on a novel biological target involved in neutrophil-driven hyperinflammatory diseases, such as inflammatory bowel disease, IBD, an area of significant unmet medical need. The collaboration, supported by the prestigious Eureka grant brings together three complementary capabilities. Evogen's KEMPAS AI engine, Cystasis proprietary pathway profiler technology for high content functional validation in patient-specific models, and the clinical expertise of Ludwig Maximilian University Hospital. By integrating AI-driven molecular design, advanced functional biology, and clinical insights from the earliest stages, we aim to accelerate the identification of high-quality drug candidates while building strong long-term therapeutic and commercial value. In January this year, we announced a collaboration with Unravel Biosciences that focuses on a newly discovered target for demyelinating disorders, such as multiple sclerosis. to develop brain-penetrant therapies capable of restoring myelin and improving neurological function. Here, by combining Evogen's Campus AI drug design engine with Unravel's patient-derived molecular profiling capabilities, we are accelerating the identification of drug candidates and addressing a major unmet medical need in a neurodegenerative market exceeding $26 billion, thereby creating significant long-term partnering and commercial opportunities. This collaboration exemplifies the strategic partnerships we are pursuing by bringing together deep biological insight and evidence as that computational chemistry platform to create differentiated first-in-class therapeutic opportunities with strong pharmaceutical licensing potential. In mid-February, we announced an additional collaboration that focuses on addressing chemotherapy resistance, one of the major challenges that limits the effectiveness of current cancer treatments, in collaboration with Dr. Mark Adams and the Queensland University of Technology in Australia. Together, we are targeting a newly identified cellular detoxification pathway that enables tumors to resist cancer therapy. The collaboration integrates Evogen's campus AI generative molecular design engine with advanced cancer genomic expertise to develop novel small molecule inhibitors designed to restore treatment sensitivity. By addressing a key resistance mechanism across multiple cancer types, including non-small cell lung cancer, this program has the potential to generate differentiated oncology candidates with strong clinical and commercial value. I am very proud to present for the first time the Small Molecules Part-Times of Evergen's Pharma Division, a growing and highly promising portfolio that reflects the strengths of our technology, innovation, and strategic collaborations. We are encouraged by the advancement of the molecules generated in collaboration with our partners, and we look forward to seeing these programs progress rapidly into more advanced preclinical and clinical stages. At the same time, we expect additional high-potential projects to join this exciting pipeline, further expanding the opportunities ahead of us. Looking ahead, I am excited to continue sharing updates on meaningful progress we are making across these programs. With that, I would like to conclude my remarks and hand over the call back to Ofer.

Thank you, Gaby. We will conclude the update on the Compact Score business activities with the status in the field of ad-clinical development. Operations in this field are conducted through our subsidiary, ActPlanus. I will ask Dr. Dan Gelvan, ActPlanus' CEO, to elaborate on the company's activities.

Thank you, Ofer. I am pleased to provide an update on the status of ActPlanus' activities since the beginning of 2026. The main progress has been in our internal project aimed at developing a fungicide for Septoria, and I will elaborate on this topic on the coming two slides. But first, I would like to focus on an update regarding our collaboration with Bayer. While Aplena's collaboration with Bayer has yielded significant novel active compounds, thereby thoroughly validating our ability to optimize active molecules, It has now become evident that these candidates cannot be further developed due to issues pertaining to the biology of the target protein. As a result of this inherent target problem, we have amicably, together with Bayer, decided to terminate our research collaboration agreements. Based on the strong professional relationship established during this collaboration, we are now exploring potential opportunities for future collaborations that would leverage Akpela's computational chemistry capabilities, discovery platforms and module optimization expertise as demonstrated throughout this collaboration. I will be happy to update on the outcomes of these discussions in future updates. Within our internal development pipeline, we are making good progress in developing a new fungicide for wheat blotch as a disease caused by Zymocytorrhoids vartesi. We are working to address a major problem representing an annual market value of over $1.2 billion. Approximately 70% of fungicides applied to wheat in Europe are aimed at fighting wheat blotch. Concurrently, many existing products, such as strobilurins, are experiencing diminished efficacy as the disease develops resistance. This underscores the critical need for a new and effective solution. Our initial assessment was not promising, as no structural data was available for the target protein, a common challenge in egg chemistry research aimed at overcoming resistance. We used homology modeling and structure-based pharmacophore development to characterize the active site. Utilizing Pointed, the initial phase of molecule screening employing Kempass AI, 440 candidates were selected for testing. Of these, only 11 met the enzymatic inhibition thresholds and only two demonstrated antifungal activity. From these two in vitro and in vivo validated compounds and incorporating the negative results, utilizing active search, The subsequent phase of molecule screening that leveraged the data generated in the preceding stage, we selected 164 off-the-shelf molecules for purchase. Subsequently, 38 of these showed enzymatic inhibition and 5 demonstrated antifungal activity, demonstrating a clear improvement over the initial screening. Building on these insights, we moved to lead-up GPT and generated 27 novel compounds, which were custom synthesized and tested over the past month. Of these, 25 metenzymatic inhibition thresholds and 15 also showed the desired biological activity, which represents a dramatic improvement. This progression illustrates how the integration of iterative experimental validation with AI-driven molecular design can transform limited early signals into a focused, high-quality lead set. We have high expectations for this program, and I will be pleased to update you on the progress we make in the coming quarters. I'm pleased to present and add a plenus pipeline to that of Evogen's Pharma division. I believe that consolidating these two activities on a single technological platform will create strong synergy and mutual enrichment, thereby accelerating product development in both areas and strengthening our competitive advantage and value proposition across the two industries in which we operate. With that, I conclude my remarks and hand the presentation back to Olga.

Thank you Dan. Looking ahead, we anticipate meaningful progress across all three of the company's core areas of activity, reinforcing our growth, trajectory, and long-term value creation. With respect to our technology engine, we continue to strengthen our competitive edge through the expansion of additional technological collaborations designated to further enhance our innovation capabilities and sustain our unique market advantage. Looking at our drug development activity for the pharmaceutical industry, we are expecting to advance our existing pipeline toward key value-creating milestones, establishing new strategic collaborations with leading biotech companies and academic institutions, deepening relationships with global pharmaceutical companies, and actively evaluating new opportunities to establish our internal drug development pipeline. With respect to our clinical development activity for the agriculture industry, we expect a continued advancement of our existing pipeline assets, forming new collaboration with leading ag chem companies and ongoing evaluation of opportunities to expand and strengthen our internal pipeline. Overall, we remain strongly focused on executing partnership extension and pipeline development across all business areas, positioning the company for sustained growth and long-term success. With this, I conclude my part and hand over the discussion to Polina. This is her first time participating in Portal Ecole, and I would like to wish her great success as the lead Evogenz finance department. Good luck, Polina.

Thank you, Ofer. Before I move on to the update regarding the first quarter financial statements, I would like to provide an update on the activities of EgoGen's subsidiaries that, in line with our revised strategy, are no longer part of our core business focus. Three companies fall into this category, LaviBio, Biomica and Costera. We will begin with an update regarding the companies with activities we have decided to discontinue and significantly scale down LaviBio and Biomica. LaviBio's activity evidence of failure in the field of agro-biologicals was inquired by ICL in 2025. The revised operations were discontinued at the end of the first quarter of 2026. We are distributing the remaining cash balance accumulated in the company as a result of the sale of the operations to ICL. The company expects to receive two additional payments under this transaction. With respect to Biomeca, Evagent subsidiary in the field of therapeutics based on the human microbiome, frequent significant events have occurred since the beginning of the year. Biomic is licensed as a lead oncology candidate, BMC-128, positioned for pharmaceuticals in early 2026. Biomic is currently completing a phase 1 clinical trial for BMC-128. Biomeca has recently received approval to distribute the company's remaining cash to its shareholders. We will continue to provide updates on these three matters in the coming quarter. We will now move on to the update regarding Castera, our subsidiary in the capital cultivation sector for oil production for bioproducts and alternative energy. As previously noted, although this activity is not part of our core business, The activity is ongoing, and we are evaluating its potential primarily in Brazil. I would like to note that Costera's operations have also undergone a significant reduction in recent months in order to align its activities with Brazil only. As we noted in the previous quarter, we are evaluating the potential inherent in Costera's operations in Brazil. As part of this activity, we were pleased to report two significant events. In April, we reported strong results in terms of yield and agronomic performance of our varieties in commercial scale trials in Brazil. In May, we reported that the company is conducting approximately 13 field trials of our Cornell shell and new varieties in seven target regions in Brazil under different cultivation regimes. The extent of this activity will form the basis for the commencement of sales in Castera Seeds for its 2027 growing season. Now we will move on to present the company's financial statements for the first quarter of the year, and we'll begin with the balance sheet. Let's start with our cash position. As of March 31st, 2026, Average & Health consolidated cash, cash equivalents, and shortened bond deposits of approximately 13.1 The consolidated cash usage during the first quarter of 2026 was approximately $2.8 million. During the first quarter of 2026, Navibuy received court approval for the distribution of a $4.25 million dividend to its shareholders. In April 2026, Biomica received court approval for the distribution of a $2.7 million dividend to its shareholders. Both the distribution processes are expected to be completed in the second quarter of the year. In February 2026, Evogen entered into a warrant inducement agreement with an existing investor for the immediate exercise of all August 2024 Series A and Series B warrants, resulting in a gross proceeds of approximately $3.4 million before fees and expenses. Consideration for the exercise when investors received in a private placement new under-districted Series A1 and Series B1 warrants to purchase up to an aggregate of 5,036,924 ordinary shares. The new warrants are immediately exercisable and exercise price of $1.25 per share. The Series A1 and Series B1 warrants were classified as a liability in the consolidated statements of financial position, initially recorded as fair value, and subsequently remeasured at each reporting date using that shows option price and model. As of March 31st, 2026, the warrant liability totaled to approximately $1.7 million. We will now focus on the income statement. Revenues for the first quarter of 2026 totaled approximately $0.3 million, compared to approximately $2.3 million in the same period of 2025, representing a decrease of approximately $2 million. The decrease is mainly attributable to lower revenue recognized by Castera, which in the first quarter of 2025 included significant seed sales of approximately $2 million. Cost of revenues for the first quarter of 2026 was approximately $0.1 million, compared to approximately $1.5 million in the corresponding period of 2025. The difference in cost of revenues is consistent with the decline in revenues during the quarter. Research and development expenses net of non-refundable grants for the first quarter of 2026 were approximately $1.8 million, compared to approximately $2.5 million in the corresponding period 2025, representing a decrease of approximately $0.7 million. The decrease is mainly attributable to lower R&D expenses in Biomica, Castera, and Atlenos. Standard marketing expenses for the first quarter of 2026 and 2025 were approximately $0.4 million, with no material change between the periods. General administrative expenses for the first quarter of 2026 remained stable at approximately $1.2 million compared with the corresponding period of 2025. Although there was a material decrease in the company's G&E expenses, it was substantially offset by the impact of exchange rate fluctuations between the U.S. dollar and the NIS, as well as transaction costs related to the warranty of use and production. Other income net of approximately $30,000 was recorded in the first quarter of 2026, mainly due to the sale of fixed assets, compared to other income of approximately $191,000 recorded in the third quarter of 2025, which was mainly related to the accounting treatment associated with EvoGen's established agreement. Operating loss for the third quarter of 2026 was approximately $3.2 million, compared to approximately $3 million in the corresponding period of 2025. The increases in operating loss is mainly due to decreased revenues, partially offset by lower operating expenses, as described in the move. Financing expenses net for the first quarter of 2026 were approximately $2.7 million, compared to financing income net of approximately $1.1 million in the corresponding period of 2025. The change was primarily due to the accounting treatment of pre-funded warrants, and warrants issued in the August 2024 fundraising, and warrants issued in the February 2026 Warrant & Usement Transaction. As part of the February 2026 Warrant & Usement Transaction, the company recorded financial expenses of approximately $3.8 million during the first quarter of 2026, partially offset by financial income of approximately $0.9 million related to the regulation of warrants. Income from discontinued operations net for the first quarter of 2026 was approximately $40,000, compared to a loss from discontinued operations net of approximately $1.1 million in the corresponding period of 2025. These amounts primarily reflect the financial results of the V-BIAS operation as well as expenses related to the development and maintenance of MicroBoost AI for Ag, which are presented as a single line item in the consolidated statements of profit and loss. Following the sale of majority of the VBI's assets, as well as average and MicroBoost AI for Ag in July 2025, the VBI no longer maintains its lease and its operating expense level has decreased significantly. Net loss for the first quarter of 2026 was approximately $5.9 million, compared to approximately $3 million in the same period last year. The increase of approximately $2.9 million was mainly due to decrease in revenues and increase in net financing expenses, partially offset by decrease in operating expenses and reduced loss from discontinued operations. Next. I now conclude my remarks and will open the call for questions.

Thank you. Ladies and gentlemen, at this time we will begin the question and answer session. In order to send the question, use the chat button located at the bottom of your screen. Please type your full name and your company's name before the question. The first question, when can you sign a strategic deal via tech partner, pharma partner, ag partner that would include an investment into the shares?

This is Ofer, and I see that this question came from Patrick, which I'm really happy to hear from him. It's been a while since we were in contact. Well, I think that trying to project when transactions took place, it really depends on the progress and results we achieved in the different areas that you mentioned. I think that since Evogen through X-Planus is highly active in the access core, and we already have over there some very significant results, as was presented today by Dan, I intend to believe that this is one of the first places where we can see a specific transaction that might, not necessarily, but might also include equity investments, but definitely should be something that is meaningful for the ad plans and also, of course, definitely for EvoGen. So this is one of the areas that I believe could represent a catalyst, the way that you described, in the next, in the future. The next area, actually, is technology. I believe that over there, since we are working with some big names, companies such as Google, and I can also maybe disclose that we are working with some other companies in the same size as Google, where we are looking for an area to collaborate with them and expand our technology advantage. I think that these type of companies or similar to Google could be another area that maybe after the ag could lead to a significant transaction. In the pharma, once again, I would like to emphasize the point that we initiate our activities only at the beginning of 2025. And the fact that today we have actually four online collaborations in this area, and we are now talking with some other partners on additional collaboration, it's very, very impressive, and I'm really excited about it. Still, in order to convince the big pharma or the big biotech companies to adapt our technology in a way that it will lead to a significant subtraction in equity investment, it will take a while. I'm not talking about many years, but I'm not talking about, of course, it's not going to be in the next few quarters. The good news is that we have already started the discussion with Big Pharma. Of course, I cannot discuss the name in this case. There is an interest in what we are doing, and I believe that when we start to see results coming from our ongoing collaboration in this market segment, it will be much easier for us to start to build a relationship with the Big Pharma companies. which, like Iran, hopefully can lead to the type of strategic collaboration that can also involve equity investments. So I think that we are in the right direction. And actually, each segment is feeding the provisional success of the other segments. So a success in the ag will feed the potential success in the technology segment. And of course, both of them are going to feed the probability of success or such an engagement with the big pharma in the pharma industry. I hope that answers your question.

I repeat, in order to send a question, use the chat button located at the bottom of your screen. Please type your full name and your company's name before asking a question. There are no further questions at this time. Mr. Habib, would you like to make a concluding statement?

Yes, thank you, and I really appreciate the time of all the people that participated in this analyst call, and we are all looking forward to continue to update you on the POMBI progress, and I really hope that we continue with the same speed of new collaboration and agreement like we did at the beginning of this year. Thank you very much.

This concludes EvoGen's first quarter 2026 results conference call. Thank you for your participation. You may go ahead and disconnect.